Sinovac posts positive PhI/II data for their Covid-19 vaccine as researchers rush into a pivotal test

John Carroll

Editor & Founder

Beijing-based Sinovac has posted a positive preliminary snapshot of human data from the Phase I/II study of their vaccine for coronavirus, showing that the jab …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sinovac posts positive PhI/II data for their Covid-19 vaccine as researchers rush into a pivotal test

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sino­vac posts pos­i­tive PhI/II da­ta for their Covid-19 vac­cine as re­searchers rush in­to a piv­otal test

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sinovac posts positive PhI/II data for their Covid-19 vaccine as researchers rush into a pivotal test